Back to results
US 12,409,184 B2Granted
Iloprost compositions and formulations thereof
AssigneeBTG International Limited
InventorsWade W. Benton, Kevin A. Christal
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.
Claims12
A pharmaceutical composition formulated for injection, comprising a pre-dilution formulation comprising:
- i. about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the pre-dilution formulation;
- ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the pre-dilution formulation;
- iii. sodium chloride;
- and
- iv. ethanol;
- wherein the pre-dilution formulation has a pH of about 8 to about 9;
- and
- wherein the pre-dilution formulation is diluted by about 100-fold prior to injection to form the composition for injection, said composition for injection being stable for up to 4 hours at 20° C. to 25° C.
5 more elements
Dependencies are inferred from the claim text.